Other languages Galectin Therapeutics Inc.

Equities

GALT

US3632252025

Market Closed - Nasdaq Other stock markets 04:15:00 2024-05-03 pm EDT			5-day change	1st Jan Change
3.34 ^USD	-0.89%		-4.57%	+101.20%

Mar. 29	Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	CI
Mar. 29	Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	Mar. 29
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Galectin Says Data and Safety Monitoring Board Approves Continuation of Belapectin Study Without Modifications.	23-10-03
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE	23-10-03
Galectin Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Galectin Therapeutics Files $100 Million Mixed Shelf	23-04-17
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
Galectin Therapeutics Cleared by DSMB to Continue Belapectin Study in Patients with Liver Cirrhosis Caused by NASH	23-03-16
Galectin Therapeutics Inc. Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis	23-03-16
Galectin Therapeutics Inc. Provides Final Randomization Status of Navigate, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis	23-03-02
Galectin Therapeutics Inc. Announces the End of Enrollment of Navigate, Its Seamless, Adaptive Phase 2B/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis	23-01-05
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
Galectin Therapeutics Files Investigational New Drug Application for Proposed Head, Neck Cancer Treatment With US FDA	22-10-12
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer	22-10-12
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE	22-10-06
Galectin Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15
Galectin Gets $60 Million Line of Credit From Chair Richard Uihlein to Cover Expenditures Through 2024	22-07-26
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress(TM) 2022	22-06-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Galectin Therapeutics Inc.

Equities

GALT

US3632252025

Other languages

Filters